Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutatio...
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
About this item
Full title
Author / Creator
Li, Meng-Xia , He, Hao , Ruan, Zhi-Hua , Zhu, Yu-Xi , Li, Rong-Qing , He, Xiao , Lan, Bao-Hua , Zhang, Zhi-Min , Liu, Guo-Dong , Xiao, Hua-Liang , Wu, Yan , Zhu, Bo , Wang, Ge and Yang, Zhen-Zhou
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line treatment for CNS metastasis NSCLC patients with EGFR-sensitizing...
Alternative Titles
Full title
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0bc162c5ca1e4caa8aee00e10ad55199
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0bc162c5ca1e4caa8aee00e10ad55199
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-017-3165-0
